(Q36292851)

13 August 2017

Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer (English)

1 reference

13 August 2017

phase II clinical trial

0 references

1 reference

1 reference

1 reference

Matsui K

1

1 reference

13 August 2017

Masuda N

2

1 reference

13 August 2017

Fukuoka M

3

1 reference

13 August 2017

Yana T

4

1 reference

13 August 2017

Hirashima T

5

1 reference

13 August 2017

Komiya T

6

1 reference

13 August 2017

Kobayashi M

7

1 reference

13 August 2017

Kawahara M

8

1 reference

13 August 2017

Atagi S

9

1 reference

13 August 2017

Ogawara M

10

1 reference

13 August 2017

Negoro S

11

1 reference

13 August 2017

Kudoh S

12

1 reference

13 August 2017

Furuse K

13

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 June 1998

1 reference

British Journal of Cancer

13 August 2017

1 reference

13 August 2017

77

1 reference

13 August 2017

11

1 reference

13 August 2017

1961-1965

1 reference

Phase I/II trial of etoposide and carboplatin in extensive small-cell lung cancer. A report from the Cancer and Leukemia Group B.

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150367

Is carboplatin and oral etoposide an effective and feasible regimen in patients with small cell lung cancer?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150367

Carboplatin/etoposide combination chemotherapy in the treatment of poor prognosis patients with small cell lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150367

Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150367

Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150367

Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150367

Chronic daily administration of oral etoposide--a phase I trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150367

VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150367

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150367

A phase II study of oral etoposide in elderly patients with small cell lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150367

Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150367

Single-agent oral etoposide for elderly small cell lung cancer patients.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150367

Determining carboplatin/etoposide dosage in extensive stage small-cell lung cancer (SCLC)

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150367

VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150367

cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150367

Role of chemotherapy in small cell lung cancer: a consensus report of the International Association for the Study of Lung Cancer workshop

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150367

Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150367

Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150367

Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150367

Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150367

Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia

22 September 2018

1 reference

12 December 2020

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer

1 reference

12 December 2020

Oral etoposide and carboplatin. Effective therapy for elderly patients with small cell lung cancer

1 reference

12 December 2020

Prediction of carboplatin clearance from standard morphological and biological patient characteristics

1 reference

12 December 2020

Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B

1 reference

12 December 2020

Influence of age on the treatment of limited-stage small-cell lung cancer

1 reference

12 December 2020

Treatment of small cell lung carcinoma in the elderly

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1998.325

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

9667675

1 reference